TICK-BORNE ENCEPHALITIS (TBE) VACCINE

Katherine Poehling, M.D.
Chair, ACIP TBE Vaccine Work Group
February 24, 2021
# TBE Vaccine Work Group members and participants

<table>
<thead>
<tr>
<th>ACIP</th>
<th>ACIP liaisons</th>
<th>Technical advisors (cont’d)</th>
<th>CDC participants (cont’d)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kathy Poehling (Chair)</td>
<td>David Shlim, ISTM</td>
<td>Kayvon Modjarrad, DOD</td>
<td>Caitlin Cossaboom, DHCPP</td>
</tr>
<tr>
<td>Wilbur Chen</td>
<td>Mark Sawyer, AAP</td>
<td>Steven Schofield, CATMAT</td>
<td>Stacey Martin, DVBD</td>
</tr>
<tr>
<td>CDC lead</td>
<td>Technical advisors</td>
<td>Bryan Schumacher, DOD</td>
<td>Michael McNeil, DHQP</td>
</tr>
<tr>
<td>Susan Hills, DVBD</td>
<td>Mary Wilson, Univ Calif SFO</td>
<td></td>
<td>Rebecca Morgan, Consultant</td>
</tr>
<tr>
<td>Alan Barrett, Univ Texas Galveston</td>
<td></td>
<td>Erin Staples, DVBD</td>
<td></td>
</tr>
<tr>
<td>Lin Chen, Mount Auburn Hosp</td>
<td></td>
<td>Steve Waterman, DVBD</td>
<td></td>
</tr>
<tr>
<td>Ex Officio</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Katherine Kinder, DOD</td>
<td></td>
<td>Grace Appiah, DGMQ</td>
<td></td>
</tr>
<tr>
<td>Rodolfo (Rudy) Alarcon, NIH</td>
<td>Tony Marfin, PATH</td>
<td>Doug Campos-Outcalt, Consultant</td>
<td>Jessica MacNeil, NCIRD</td>
</tr>
<tr>
<td>Ihid Carneiro Leao, FDA</td>
<td>Bruce McClenathan, DOD</td>
<td>Susan Chu, GID</td>
<td>Amanda Cohn, NCIRD</td>
</tr>
</tbody>
</table>
Background

- Pfizer has submitted a Biologics License Application (BLA) to Food and Drug Administration (FDA) for their TBE vaccine
- Licensure possible by 3rd quarter of 2021
- No TBE vaccine previously licensed in the United States
- No existing ACIP TBE vaccine recommendations
Terms of Reference for TBE Vaccine Work Group

- To review information on TBE, including its epidemiology, clinical presentation, diagnosis, treatment, and outcome
- To review data on infection risk and burden for U.S. civilian and military travelers and laboratory workers
- To review data on vaccine safety, immunogenicity, and effectiveness
- To provide evidence-based recommendation options for ACIP
- To identify areas in need of further research for informing potential future vaccine recommendations
- To publish ACIP recommendations in the Morbidity and Mortality Weekly Report (MMWR)
Today’s topics

- TBE epidemiology in TBE endemic areas
  - Susan Hills (CDC/NCEZID)

- TBE among US civilian travelers and laboratory workers
  - Erin Staples (CDC/NCEZID)

- TBE and the Department of Defence experience
  - Bruce McClenathan (DoD)

- Summary and next steps for TBE Vaccine Work Group
  - Susan Hills (CDC/NCEZID)
Work Group timeline (planned), Feb 2021–Oct 2021

Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sept | Oct | Nov
---|---|---|---|---|---|---|---|---|---|---

(Today)
TBE epidemiology in endemic areas and traveler and laboratory worker risk data

Present to ACIP:
GRADE (vaccine safety/immunogenicity) and EtR

Possible licensure

ACIP vote on vaccine recommendations and finalize MMWR